Stay updated with breaking news from Compassionate Use Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum...
Ivermectin battle continues as health body to challenge court order Share Cape Town – The SA Health Products Regulatory Authority (Sahpra) said it would appeal the part of a high court order requiring it to report back every three months regarding access to ivermectin for use as a treatment in Covid-19 patients. This follows a victory for several parties including the ACDP, Doctors for Life, “I Can Make a Difference” group of medical practitioners, AfriForum and others in the Pretoria High Court when Judge Cassim Sardiwalla ordered that ivermectin be made available and accessible on p...